In Clinical

Follow this topic

Bookmark

Record learning outcomes

In an open-label study of women with metastatic breast cancer, eribulin plus capecitabine produced an overall response rate of 42.9 per cent, the San Antonio Breast Cancer Symposium heard. Furthermore, 57.1 per cent of patients showed a clinical benefit and the median progression free survival was 7.1 months.

Meanwhile the EC recently granted marketing authorisation for ramucirumab (Cyramza) which, manufacturer Eli Lilly says, is the first licensed therapy specifically for adults with advanced gastric or gastrooesophageal junction adenocarcinoma following chemotherapy. Ramucirumab is combined with paclitaxel or used as monotherapy when paclitaxel is not appropriate.